GRAIL faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Click here to ...

Illumina Inc. closed $13.90 short of its 52-week high ($144.02), which the company achieved on January 31st.

After hours: September 27 at 4:45 PM EDT ...

The stock's rise snapped a four-day losing streak.

Illumina completed the deal just under a year later, bringing Grail back under its ownership, having previously spun the company out. Only three years after the arrangement was struck, Illumina ...

BRUSSELS (Reuters) -U.S. gene sequencing company Illumina on Tuesday won its court fight against the European Union's investigation of its $7.1 billion purchase of cancer diagnostic test maker ...

On Thursday, Illumina Inc (ILMN) stock saw a modest uptick, ending the day at $132.27 which represents a slight increase of $6.12 or 4.85% from the prior close of $126.15. The stock opened at $128.04 ...

BRUSSELS, Sept 3 (Reuters) - U.S. gene sequencing company Illumina (ILMN.O), opens new tab on Tuesday won its court fight against the European Union's investigation ...

Throughout Illumina’s more than four-year saga to acquire liquid biopsy company Grail, it insisted the opposition from European regulators has no basis in law. Europe’s highest judicial body ...

Illumina Inc (ILMN) stock saw a decline, ending the day at $128.82 which represents a decrease of $-1.28 or -0.98% from the prior close of $130.1. The stock opened at $130.49 and touched a low of $128 ...